panel of markers that are easily measured from the man's genetic background that would indicate the likelihood that he's going to have an aggressive course of his disease or not," said study co-author Janet L. Stanford 
N E W S
"From that cohort, we identified 22 individual SNP markers that were strongly associated with death from metastatic prostate cancer in our population," said Stanford.
They then took the 22 SNPs to colleagues at the Karolinska Institutet in Stockholm and Umea University in Umea, Sweden. The Swedish researchers genotyped the same 22 SNPs in another populationbased group of 2,875 prostate cancer patients in Sweden in the same age group as their American counterparts. Two SNPs failed genotyping in the Swedish population, and five of the remaining 20 SNPs were validated as being statistically significantly associated with death from prostate cancer.
The five SNPS included the following:
LEPR (or LEP-R).
LEP-R was the strongest marker associated with prostate cancer mortality. It functions as a receptor for the fat cell-specific hormone leptin and helps control tissue growth, inflammation, bloodvessel development, and bone density. Stanford said LEPR is an interesting candidate for understanding disease progression, because the primary metastatic site for prostate cancer is bone and is fatal.
2. RNASEL. RNASEL is associated with inherited prostate cancer. It is associated with apoptosis (programmed cell death), inflammation, and cell proliferation, a feature of cancer cells.
Interleukin 4 (IL-4).
The IL-4 gene stimulates the immune system to develop mast cells, resting T cells, and activated B cells. IL-4 is associated with tumor growth, blood vessel development, and cancer cell migration.
4. Cryptochrome 1 (CRY1). CRY1 affects circadian rhythm and may affect androgen levels, which are involved in prostate cancer progression.
Armadillo Repeat gene deleted in velo-cardio-facial syndrome (ARVCF).
ARVCF is a member of the catenin family of proteins, which play an important role in the formation of adherens junction complexes, believed to facilitate communication between the inside and outside of cells. Stanford said increased expression of ARVCF disrupts cell adhesion, which may facilitate cancer progression.
Stanford said that men in the study who carried four or all five of these genetic markers had a 50% higher risk of dying from their prostate cancer than patients who had two or fewer.
Not So Fast . . .
Having this type of genetic information at hand may be particularly beneficial for understanding such a heterogeneous disease whose progression may take place over several years. When the disease is first diagnosed, clinicians face the problem of what treatment to recommend, because they don't fully understand how to predict how aggressive the tumor will become. Because the course of the disease is unpredictable, men who have indolent, slowgrowing tumors are often overtreated. At the other end of the spectrum are undertreated men, who have more aggressive disease and don't know it, and postpone aggressive therapy.
Although current early detection guidelines from organizations including the National Cancer Center Network and the American Urological Association recommend biopsies for elevated or a rapid rise in prostate-specific antigen (PSA), a recent study found that change in PSA levels over time, known as PSA velocity, is a poor predictor of prostate cancer that often leads to unnecessary biopsies.
The study, published in the Feb. 24 issue of the Journal, included more than 5,000 men and found no evidence that men with a high PSA velocity should undergo biopsies in the absence of other indications. "In other words, if a man's PSA has risen rapidly in recent years, there is no cause for concern if his total PSA level is still low and his clinical exam is normal," said lead author Andrew Vickers, Ph.D., an associate attending research methodologist in the department of epidemiology and biostatistics at the Memorial Sloan-Kettering Cancer Center in New York. But this conclusion doesn't solve the underlying problem: who should be treated aggressively and who can afford watchful waiting.
More Research Needed
The current biomarker study bumps the issue a bit forward, Vickers said, explaining that researchers have long struggled to actually find germline mutations in prostate cancer that affect its aggressiveness. "It's very nice to see we've finally identified some genes that actually do predict aggressive prostate cancer," Vickers said.
Still, further study is needed, Vickers added. "They've provided very strong evidence of their hypothesis, which is that certain germline mutations lead to aggressive prostate cancer," he said. "However, the size of that effect is actually very small, and that's why I doubt the clinical value at this time. I doubt that anytime soon, we're going to be giving gene tests to prostate cancer patients."
Shuji Ogino, M.D., Ph.D., at the DanaFarber Cancer Institute in Boston, agreed that the study is an important step in understanding prostate cancer but that the researchers need to go further. "While this is an advance, a large piece is missing," he said. "Tumor molecular features need to be considered in this context of germline variants."
For now, Stanford said her team at Fred Hutchinson is now seeking additional cohorts-including those with fatal events and patients undergoing a variety of treatments-to test all 22 SNPs to validate the original five and to see whether others emerge as more statistically significant.
"We are working very hard to try and find better biomarkers that would help distinguish different subsets of patients," she said. "That would be beneficial for helping patients make decisions about treatments, and for physicians to make better recommendations about treatments."
